Skip to content

Study · Ex vivo tissue · 1993

3 results

Epithelium removal and peptidase inhibition enhance relaxation of human airways to vasoactive intestinal peptide.

Hulsmann AR, Jongejan RC, Rolien Raatgeep H, Stijnen T, Bonta IL, Kerrebijn KF, De Jongste JC

The American review of respiratory disease1 Jun 1993Cited by 4 (Europe PMC)

PMID8503559 (opens in a new tab)DOI10.1164/ajrccm/147.6_pt_1.1483 (opens in a new tab)PepBankPUB-08503559
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabEx vivo tissueEfficacy outcome

    In isolated human central and peripheral airways with intact epithelium, VIP caused only minor relaxation.

    In plain wordsIn lab tests on human airways, VIP relaxed intact airway tissue only slightly.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreaseRelaxation of intact airways to VIP
    Study

    humann = 8

    Isolated human airway strips in organ baths
    Outcome group
    Respiratory function · Respiratory
    Studied dose
    10(-10) to 10(-7) M · organ bathAs given in this study (human).

    Source sentences

    Summary
    Both intact central and peripheral airways showed only minor relaxations to VIP irrespective of the precontraction level.
    1 context sentence
    Summary · context
    Human airways were obtained at thoracotomies (n = 8) and studied in organ baths.
  2. 02LabEx vivo tissueEfficacy outcome

    In isolated human airways, removing the epithelium and adding peptidase inhibitors additively increased the sensitivity to VIP by more than 20-fold.

    In plain wordsIn lab tests on human airways, removing the lining and blocking peptide-degrading enzymes made the tissue far more sensitive to VIP.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreaseSensitivity to VIP after epithelium removal and peptidase inhibitors
    Study

    humann = 8

    Isolated human airway strips in organ baths
    Comparator
    Intact airways without peptidase inhibitors
    Outcome group
    Respiratory function · Respiratory
    Studied dose
    10(-10) to 10(-7) M · organ bathAs given in this study (human).

    Source sentences

    Summary
    Removal of the epithelium and addition of peptidase inhibitors additively increased the sensitivity (> 20-fold) and maximal response to VIP in both central and peripheral airways.
    1 context sentence
    Summary · context
    Human airways were obtained at thoracotomies (n = 8) and studied in organ baths.
  3. 03LabEx vivo tissueEfficacy outcome

    In isolated human airways, removing the epithelium and adding peptidase inhibitors additively increased the maximal response to VIP.

    In plain wordsIn lab tests on human airways, removing the lining and blocking peptide-degrading enzymes increased the largest relaxation response to VIP.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreaseMaximal relaxation to VIP after epithelium removal and peptidase inhibitors
    Study

    humann = 8

    Isolated human airway strips in organ baths
    Comparator
    Intact airways without peptidase inhibitors
    Outcome group
    Respiratory function · Respiratory
    Studied dose
    10(-10) to 10(-7) M · organ bathAs given in this study (human).

    Source sentences

    Summary
    Removal of the epithelium and addition of peptidase inhibitors additively increased the sensitivity (> 20-fold) and maximal response to VIP in both central and peripheral airways.
    1 context sentence
    Summary · context
    Human airways were obtained at thoracotomies (n = 8) and studied in organ baths.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.